247 related articles for article (PubMed ID: 32694900)
1. Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study.
Zhao W; Bian L; Wang T; Zhang S; Li J; Xu F; Jiang Z
Chin J Cancer Res; 2020 Jun; 32(3):361-369. PubMed ID: 32694900
[TBL] [Abstract][Full Text] [Related]
2. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of margetuximab plus chemotherapy
Zhang Q; Ouyang Q; Li W; Chiu J; Yan M; Lu YS; Sun S; Li H; Du Y; Wang X; Sun T; Yin Y; Wang H; Ye F; Shen K; Wang J; Pan Y; Wang S; Yang J; Wu X; Dai MS; Cheng J; Teng Y; Su F; Wu X; He J; Fu P; Yang L; Xin Y; Wang X; Jiang Z
Transl Breast Cancer Res; 2022; 3():31. PubMed ID: 38751523
[TBL] [Abstract][Full Text] [Related]
4. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305
[TBL] [Abstract][Full Text] [Related]
5. Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: A multicenter, retrospective study.
Xie Y; Ge R; Sang D; Luo T; Li W; Ji X; Yuan P; Wang B
Cancer Med; 2020 May; 9(9):2981-2988. PubMed ID: 32108439
[TBL] [Abstract][Full Text] [Related]
6. Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
Li Y; Gong C; Lu Q; Zhou Z; Luo T; Li W; Li G; Ge R; Xu F; Wang B
Front Oncol; 2020; 10():271. PubMed ID: 32195186
[No Abstract] [Full Text] [Related]
7. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study.
Gui X; Li H; Yan Y; Zhang R
Oncol Lett; 2020 Dec; 20(6):378. PubMed ID: 33154776
[TBL] [Abstract][Full Text] [Related]
9. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.
Gavilá J; De La Haba J; Bermejo B; Rodríguez-Lescure Á; Antón A; Ciruelos E; Brunet J; Muñoz-Couselo E; Santisteban M; Rodríguez Sánchez CA; Santaballa A; Sánchez Rovira P; García Sáenz JÁ; Ruiz-Borrego M; Guerrero-Zotano AL; Huerta M; Cotes-Sanchís A; Lao Romera J; Aguirre E; Cortés J; Llombart-Cussac A
Clin Transl Oncol; 2020 Mar; 22(3):420-428. PubMed ID: 31203575
[TBL] [Abstract][Full Text] [Related]
10. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
12. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer.
Ramagopalan SV; Pisoni R; Zenin A; Rathore LS; Ray J; Sammon C
J Comp Eff Res; 2021 May; 10(7):595-602. PubMed ID: 33095031
[TBL] [Abstract][Full Text] [Related]
14. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2018 Mar; 36(8):741-748. PubMed ID: 29244528
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
16. Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial.
Xie XF; Zhang QY; Huang JY; Chen LP; Lan XF; Bai X; Song L; Xiong SL; Guo SJ; Du CW
Breast Cancer Res Treat; 2023 Jan; 197(1):93-101. PubMed ID: 36309908
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
[TBL] [Abstract][Full Text] [Related]
18. Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study.
Hua Y; Li W; Jin N; Cai D; Sun J; Sun C; Yang F; Wu X; Huang X; Wang B; Yin Y
Ther Adv Med Oncol; 2022; 14():17588359221085232. PubMed ID: 35356262
[TBL] [Abstract][Full Text] [Related]
19. Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study.
You S; Sang D; Xu F; Luo T; Yuan P; Xie Y; Wang B
Ther Adv Med Oncol; 2023; 15():17588359231217972. PubMed ID: 38145113
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
